International: +1-347-960-6455
Spasticity Therapeutics - Pipeline Analysis 2018

Spasticity Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10088 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Musculoskeletal
Select License Type

Spasticity is a condition in which certain muscles are continuously contracted. The constant muscle contraction causes stiffness or tightness of the muscles and can interfere with normal movement, speech and gait in a patient. Spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement. This damage causes a change in the balance of signals between the nervous system and muscles, leading to increased activity in muscles. Spasticity negatively affects muscles and joints of the extremities and is particularly harmful to growing children. Currently available treatment options for this disease include oral medications and interventional procedures. Certain conditions that may cause spasticity are traumatic brain injury, spinal cord injury, brain damage due to a lack of oxygen, stroke, encephalitis, and meningitis.

The drug candidates of for treating this condition include, but are not limited to, Arbaclofen extended release and Botulinum toxin E. Some of the companies having drugs in spasticity pipeline are Osmotica Pharmaceutical, Ipsen Pharma, and Canbex Therapeutics Ltd.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.